TAS-114 是 dUTPase 和 二氢嘧啶脱氢酶 (DPD) 的双靶点抑制剂，可提高氟嘧啶药物的疗效。
货号:ajcx39018
CAS:1198221-21-4
分子式:C21H29N3O6S
分子量：451.54
溶解度:DMSO : 100 mg/mL (221.46 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

TAS-114 is a dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine[1].

TAS-114 (1-10 μM; 72 hours) increases the cytotoxicity of 5-Fluorouracil (5-FU) and 5-FU,2′-deoxy-5-fluorouridine (FdUrd) against various cancer cell lines in dose-dependent manner[1].

TAS-114 (37.5-1,200 mg/kg/day; orally; 1-14 days) increases the antitumor activity of 5-FU when co-administers with Capecitabine (539 mg/kg/day) in mice[1].

[1]. Yano W, et al. TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy. Mol Cancer Ther. 2018 Aug;17(8):1683-1693.